<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The authors evaluated antilymphocyte serum prepared in rabbits (ALS-R) as an alternative to antilymphocyte serum prepared in horses (ALG-H) in the therapy of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Between 1980 and 1993, 57 evaluable patients received ALS-R and <z:chebi fb="0" ids="8382">prednisone</z:chebi> +/- <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> +/- <z:chebi fb="5" ids="50113">androgens</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Standard response criteria were used and patients were evaluated at 3 months from the start of therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Median age was 43 years </plain></SENT>
<SENT sid="4" pm="."><plain>Disease was present for up to 2 months in 24 patients, 2-5 months in 14 patients, and 6 months or more in 19 patients </plain></SENT>
<SENT sid="5" pm="."><plain>Disease was severe in 30 patients and moderate in 27 </plain></SENT>
<SENT sid="6" pm="."><plain>Responses occurred in 16 (28%) of 57 patients </plain></SENT>
<SENT sid="7" pm="."><plain>Responses were more frequent in females, in patients treated within 6 months of diagnosis, and in patients with severe disease </plain></SENT>
<SENT sid="8" pm="."><plain>Among patients receiving ALS-R and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> within 2 months of diagnosis, 46% responded </plain></SENT>
<SENT sid="9" pm="."><plain>After ALS-R therapy, 20 patients received ALG-H; 8 (40%) of 20 responded </plain></SENT>
<SENT sid="10" pm="."><plain>Eight patients receiving ALS-R previously had received ALG-H; 2 (25%) of these 8 patients responded </plain></SENT>
<SENT sid="11" pm="."><plain>Toxicity of ALS-R was minimal </plain></SENT>
<SENT sid="12" pm="."><plain>Antilymphocyte serum prepared in rabbits, in conjunction with other <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi>, represents an effective alternative to ALG-H in <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, especially in patients previously treated with ALG-H </plain></SENT>
</text></document>